Phase I trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

BACKGROUND: Simultaneous inhibition of the vascular epithelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) pathway may improve treatment response in advanced renal cell carcinoma (RCC). Everolimus, an oral mTOR inhibitor, and sunitinib, an oral tyrosine kinase inhibitor (TKI) t...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Molina, Ana M., Feldman, Darren R., Voss, Martin H., Ginsberg, Michelle S., Baum, Michael S., Brocks, Dion R., Fischer, Patricia M., Trinos, Michael J., Patil, Sujata, Motzer, Robert J.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3609026/
https://ncbi.nlm.nih.gov/pubmed/21898375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26429
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires